No Detail Found!

The Impact of Nusinersen and Risdiplam on Motor Function for Spinal Muscular Atrophy Type 2 and 3: A Meta-Analysis

Author(s)
Bo Chen Zhihui Medicine and Technology College, Dazhou Vocational and Technical College,Dazhou,China
Yuanlin Gong Academic Affairs office, Dazhou Vocational and Technical College,Dazhou,China
Tengteng Zhou Zhihui Medicine and Technology College, Dazhou Vocational and Technical College,Dazhou,China
Abstract
Spinal muscular atrophy (SMA) is a prevalent paediatric neuromuscular disorder characterised by muscle weakness and atrophy resulting from degeneration of spinal cord anterior horn ± motor neurons. Gene therapy formulations exhibit varying bene ts and limitations, driving the need for patient-friendly treatment options tailored to speci c populations. The objective of this meta-analysis was to assess the e ectiveness of gene therapy for motor function in children with SMA. The analysis encompassed a total of 719 participants from six randomised controlled trials (RCTs) conducted between 2017 and 2023. Among the studies, one demonstrated a signi cant and large standardised e ect size (Cohen'sd) favouring nusinersen in terms oHfammersmith Functional Motor Scale Expanded (HFMSE) (d = 0.97) and revised upper limb module (RULM) (d = 0.96). Additionally, another study showed a moderate standardised e ect size (Cohen's d) in favour of nusinersen concerning Hammersmith Infant Neurological Examination-Section 2 (HINE-2) (d = 0.48). However, it is important to note that further research with a longer duration of observation is required to strengthen the evidence.
Publication Details
Page(s) 948-955
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 8, Year: 2024

Request the full text from PASTIC

Keywords
Spinal muscular atrophy, Motor function, Cohen's d, Nusinersen, Risdiplam
0

Citations

0

Downloads

109

Views